Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 423 recruiting now early-phase tilt #1 of 28,707 conditions

Breast Cancer: early-phase trial registry

423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1 of 28,707 conditions by registered trial count.

1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count

Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.

Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.

Enrollment posture brief

Registry condition breast-cancer

OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98

Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)

Prostate Cancer36.7%Depression35.7%Breast Cancer (this)34%Obesity28.9%Healthy20.5%
Open-enrollment share among volume-matched conditions near Breast Cancer

Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer is recruiting below its size-band peers.

    423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.

  4. Breast Cancer research is mostly interventional.

    1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1235Phase 2256Phase 3100Phase 420

Open and recent trials

1,251 total, page 18 of 26

COMPLETED 178 participants

Compliance to a Hormone Therapy Regimen in Breast Cancer

Case Comprehensive Cancer Center

NCT00666822

COMPLETED Phase 3 178 participants

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Nektar Therapeutics

NCT02915744

COMPLETED 176 participants

Lynne Cohen Consortium Project: Multi-Center Database/Registry

M.D. Anderson Cancer Center

NCT00776958

COMPLETED Phase 3 176 participants

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

North Central Cancer Treatment Group

NCT00438659

COMPLETED 172 participants

Nonlinear Elasticity Mapping of Breast Masses

Mayo Clinic

NCT04863443

COMPLETED Phase 2 170 participants

A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca

Mayo Clinic

NCT02453737

COMPLETED Phase 3 170 participants

Methods in Education for Breast Cancer Genetics

National Cancer Institute (NCI)

NCT00001806

COMPLETED Phase 1 167 participants

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Eli Lilly and Company

NCT02124148

COMPLETED NA 164 participants

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

Harold J. Burstein, MD, PhD

NCT00121134

COMPLETED NA 160 participants

SentiMag® Intraoperative Comparison in Breast Cancer

Endomagnetics

NCT02336737

COMPLETED Phase 4 157 participants

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

Hoffmann-La Roche

NCT00127933

COMPLETED NA 156 participants

Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women

Washington University School of Medicine

NCT05275361

COMPLETED Phase 2 153 participants

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Hoffmann-La Roche

NCT01196052

COMPLETED NA 153 participants

Exercise Program in Cancer and Cognition

University of Pittsburgh

NCT02793921

COMPLETED Phase 1 151 participants

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

Mayo Clinic

NCT02517593

COMPLETED 150 participants

Role of 3D Tomography in Breast Cancer

University of Rochester

NCT01090687

COMPLETED NA 150 participants

Healing Touch, Quality of Life, and Immunity During Breast Cancer Treatment

University of Iowa

NCT00565305

COMPLETED 150 participants

Intraoperative Pathway in DIEP Flap Breast Reconstruction

Beth Israel Deaconess Medical Center

NCT00543764

COMPLETED NA 147 participants

Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer

Mayo Clinic

NCT00627614

COMPLETED 145 participants

The Impact of Lymphedema on Breast Cancer Survivors

University of California, San Francisco

NCT00769821

COMPLETED Phase 2 145 participants

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Vanderbilt-Ingram Cancer Center

NCT00930930

COMPLETED Phase 2 141 participants

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

NSABP Foundation

NCT01008150

COMPLETED 141 participants

Spectroscopy of Breast Tissue

Case Comprehensive Cancer Center

NCT00918216

COMPLETED 140 participants

PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial

Walter Reed Army Medical Center

NCT00940199

COMPLETED 140 participants

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

Alliance for Clinical Trials in Oncology

NCT00516698

COMPLETED Phase 1 139 participants

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Hoffmann-La Roche

NCT03800836

COMPLETED Phase 2 135 participants

Multi-Media Imagery Program for Breast Cancer Patients (Phase II)

Mind Matters Research

NCT01034215

COMPLETED 135 participants

Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)

University of Southern California

NCT02887937

COMPLETED Phase 2 134 participants

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

Washington University School of Medicine

NCT03084536

COMPLETED 133 participants

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

Vanderbilt University

NCT00875238

COMPLETED NA 132 participants

Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery

MetroHealth Medical Center

NCT04233385

COMPLETED NA 132 participants

Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening

Beth Israel Deaconess Medical Center

NCT03482557

COMPLETED 130 participants

A Prospective Longitudinal Breast Cancer Study

Fujirebio Diagnostics

NCT02270931

COMPLETED NA 125 participants

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement

Dana-Farber Cancer Institute

NCT04879927

COMPLETED Phase 2 125 participants

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

R-Pharm

NCT00080262

COMPLETED 121 participants

Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers

Memorial Sloan Kettering Cancer Center

NCT00608452

COMPLETED NA 120 participants

Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)

NYU Langone Health

NCT02462226

COMPLETED 120 participants

Understanding the Value of Community Vital Signs in Primary Care

Virginia Commonwealth University

NCT02512835

COMPLETED 115 participants

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

University of Michigan Rogel Cancer Center

NCT01896050

COMPLETED 115 participants

Stress, Diurnal Cortisol, and Breast Cancer Survival

Stanford University

NCT00226967

COMPLETED NA 115 participants

Breast MRI as a Preoperative Tool for DCIS

Memorial Sloan Kettering Cancer Center

NCT00605982

COMPLETED NA 114 participants

Facilitating Adjustment in Low Income Black Women With Breast Cancer

University of Miami

NCT02272335

COMPLETED NA 112 participants

A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer

The University of Texas Health Science Center at San Antonio

NCT02601794

COMPLETED Phase 2 112 participants

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

Alliance for Clinical Trials in Oncology

NCT00031720

COMPLETED NA 112 participants

Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT00328783

COMPLETED Phase 2 110 participants

Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

Mayo Clinic

NCT01286168

COMPLETED Phase 2 109 participants

Docetaxel in Treating Patients With Solid Tumors

Alliance for Clinical Trials in Oncology

NCT00003565

COMPLETED 108 participants

X-Ray Mammography Standard of Care Protocol

National Institutes of Health Clinical Center (CC)

NCT01052740

COMPLETED Phase 2 108 participants

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Alliance for Clinical Trials in Oncology

NCT01439711

COMPLETED 108 participants

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT01386411

← Previous Page 18 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 235
Phase 2 256
Phase 3 100
Phase 4 20

Named interventions

Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fulvestrant Drug
33 trials
Paclitaxel Drug
32 trials
Trastuzumab Drug
26 trials
Letrozole Drug
24 trials
Pembrolizumab Drug
23 trials
Cyclophosphamide Drug
21 trials
Capecitabine Drug
20 trials
Abemaciclib Drug
19 trials

US sites by state

Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.

California 298 trials
New York 270 trials
Texas 210 trials
Florida 206 trials
Massachusetts 184 trials
North Carolina 126 trials
Illinois 123 trials
Pennsylvania 122 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast Cancer page

1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.